MLICM
RUBY

Metropolitan Life Insurance Company (MetLife)’s Rubius Therapeutics, Inc RUBY Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,160
Closed -$17.4K – 2463
2022
Q1 		$17.4K Sell
3,160
-9,199
-74% -$58.4K ﹤0.01% 2147
2021
Q4 		$120K Sell
12,359
-469
-4% -$6.5K ﹤0.01% 2370
2021
Q3 		$229K Hold
12,828
– – ﹤0.01% 1967
2021
Q2 		$313K Buy
12,828
+2,620
+26% +$65.5K ﹤0.01% 1830
2021
Q1 		$271K Buy
+10,208
New +$149K ﹤0.01% 1807
2020
Q3 		– Sell
-12,114
Closed -$72.4K – 2602
2020
Q2 		$72.4K Buy
+12,114
New +$71.5K ﹤0.01% 2425
2020
Q1 		– Sell
-10,653
Closed -$101K – 2567
2019
Q4 		$101K Sell
10,653
-1,214
-10% -$11.7K ﹤0.01% 2326
2019
Q3 		$93.2K Hold
11,867
– – ﹤0.01% 2339
2019
Q2 		$187K Hold
11,867
– – ﹤0.01% 1930
2019
Q1 		$215K Buy
11,867
+4,676
+65% +$71.8K ﹤0.01% 1863
2018
Q4 		$116K Sell
7,191
-618
-8% -$11.3K ﹤0.01% 2173
2018
Q3 		$187K Buy
+7,809
New +$179K ﹤0.01% 2048

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RUBY Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 3,160 shares — an estimated $17.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RUBY in Q3 2018 and held it in 12 quarters. The position peaked at $313K in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,160 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $17.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 12 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Rubius Therapeutics, Inc position peaked at $313K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.